These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25673333)

  • 1. Risk Factor Analysis for the Immunogenicity of Adalimumab Associated with Decreased Clinical Response in Chinese Patients with Psoriasis.
    Chiu HY; Wang TS; Chan CC; Lin SJ; Tsai TF
    Acta Derm Venereol; 2015 Jul; 95(6):711-6. PubMed ID: 25673333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
    Chiu HY; Chu TW; Cheng YP; Tsai TF
    PLoS One; 2015; 10(11):e0142930. PubMed ID: 26566272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis.
    Mostafa NM; Nader AM; Noertersheuser P; Okun M; Awni WM
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):490-497. PubMed ID: 27545848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.
    Lecluse LL; Driessen RJ; Spuls PI; de Jong EM; Stapel SO; van Doorn MB; Bos JD; Wolbink GJ
    Arch Dermatol; 2010 Feb; 146(2):127-32. PubMed ID: 20157022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial.
    Busard CI; Menting SP; van Bezooijen JS; van den Reek JM; Hutten BA; Prens EP; de Jong EM; van Doorn MB; Spuls PI
    Trials; 2017 Feb; 18(1):52. PubMed ID: 28148280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response.
    Skrabl-Baumgartner A; Erwa W; Muntean W; Jahnel J
    Scand J Rheumatol; 2015; 44(5):359-62. PubMed ID: 25974288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence.
    Lombardi G; Perego S; Sansoni V; Diani M; Banfi G; Altomare G
    BMJ Open; 2016 Dec; 6(12):e011941. PubMed ID: 27940624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis.
    Bito T; Nishikawa R; Hatakeyama M; Kikusawa A; Kanki H; Nagai H; Sarayama Y; Ikeda T; Yoshizaki H; Seto H; Adachi A; Horikawa T; Oka M; Nishigori C
    Br J Dermatol; 2014 Apr; 170(4):922-9. PubMed ID: 24329764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
    Karanikolas GN; Koukli EM; Katsalira A; Arida A; Petrou D; Komninou E; Fragiadaki K; Zacharioudaki A; Lasithiotakis I; Giavri E; Vaiopoulos G; Sfikakis PP
    J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis.
    Takahashi H; Tsuji H; Ishida-Yamamoto A; Iizuka H
    J Dermatol; 2013 Jan; 40(1):39-42. PubMed ID: 23039179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study.
    Strober BE; Poulin Y; Kerdel FA; Langley RG; Gu Y; Gupta SR; Okun MM; Papp KA
    J Am Acad Dermatol; 2011 Apr; 64(4):671-81. PubMed ID: 21414495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab for Treatment of Noninfectious Uveitis: Immunogenicity and Clinical Relevance of Measuring Serum Drug Levels and Antidrug Antibodies.
    Cordero-Coma M; Calleja-Antolín S; Garzo-García I; Nuñez-Garnés AM; Álvarez-Castro C; Franco-Benito M; Ruiz de Morales JG
    Ophthalmology; 2016 Dec; 123(12):2618-2625. PubMed ID: 27692527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases.
    Matsumoto Y; Maeda T; Tsuboi R; Okubo Y
    J Dermatol; 2013 May; 40(5):389-92. PubMed ID: 23414225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.
    Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
    J Dermatol Sci; 2014 Dec; 76(3):180-5. PubMed ID: 25306295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
    Cozzani E; Burlando M; Parodi A
    G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations.
    Marinari B; Botti E; Bavetta M; Spallone G; Zangrilli A; Talamonti M; Richetta A; Chimenti S; Costanzo A
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S11-4. PubMed ID: 25381966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study.
    Ungar B; Engel T; Yablecovitch D; Lahat A; Lang A; Avidan B; Har-Noy O; Carter D; Levhar N; Selinger L; Neuman S; Natour OH; Yavzori M; Fudim E; Picard O; Kopylov U; Chowers Y; Naftali T; Broide E; Shachar E; Eliakim R; Ben-Horin S
    Am J Gastroenterol; 2018 Jun; 113(6):890-898. PubMed ID: 29867175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
    Nakase H; Motoya S; Matsumoto T; Watanabe K; Hisamatsu T; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
    Aliment Pharmacol Ther; 2017 Nov; 46(9):873-882. PubMed ID: 28884856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.